Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study

Introduction: TriOptimize is the first ongoing real-world study of symptomatic patients with moderate-to-severe COPD treated with extrafine single inhaler triple therapy (efSITT). Methods: In this interim analysis we present the effect of 3-month treatment with efSITT (BDP/FF/G) on lung function (LF) in patients prior on LABA/LAMA, ICS/LABA or multi-inhaler triple therapy (MITT). Data were retrieved from patients’ health records if available. Results: Treatment with efSITT for 3 months resulted in improvement of airflow obstruction, airway resistance and hyperinflation parameters, showing a response pattern depending on prior treatment (Table 1). Summary and Conclusion: Symptomatic patients with moderate-to-severe COPD displayed an improvement in LF after 3 months treatment with efSITT, validating results of Phase III studies in a real-world setting. Furthermore, we report distinct therapeutic benefits of efSITT depending on the addition of a LAMA, or an ICS to prior dual maintenance therapy or possibly the single-inhaler feature compared to MITT. The improvement in LF observed after switching from MITT to single-inhaler triple therapy indicates enhanced adherence and the positive impact of using a single inhaler rather than multiple inhalers with different inhalation techniques.